AHA Tells House Panel It Opposes New 340B Hospital Reporting Requirements

Ashley Thompson
“I'm just not sure additional [340B hospital] reporting requirements are needed at this time,” AHA Senior Vice President Ashley Thompson told a U.S. House subcommittee yesterday.

An American Hospital Association senior executive told a U.S. House subcommittee yesterday her group opposes creating “significant new reporting requirements for 340B hospitals that do not reflect the true value or intent of the 340B program.”

But when asked by

Read More »

340B Abuse Claims Raised During House Hearing on Nonprofit Hospitals’ Tax Status

“Right now, there’s no transparency regarding the 340B program,” Johns Hopkins University professor Ge Bai said yesterday at a U.S. House Ways and Means oversight subcommittee hearing.

The 340B program has evolved into a “buy low, sell high” drug pricing system abused by some hospitals that have profits as their main goal, a health policy researcher told lawmakers Wednesday at a U.S. House subcommittee hearing.

The House

Read More »

Do it Yourself: 340B Referral Prescription Capture Made Easy

SPONSORED CONTENT

Many covered entities are not aware of the opportunity to capture referral prescriptions. This includes ones that were initially determined to be non-eligible by your TPA but after a closer look in your EMR are deemed to be eligible. Don’t miss out on this valuable source of revenue for your 340B program

Read More »

Louisiana Takes Major Step Towards Prohibiting Drug Manufacturer 340B Contract Pharmacy Restrictions

Louisiana House
The Louisiana House voted 97-2 to approve legislation to stop drug manufacturer interference with 340B contract pharmacy arrangements and prohibit PBM and payor practices that lower reimbursement for 340B-purchased drugs.

The Louisiana House voted 97-2 yesterday to pass and send to the Senate legislation to stop drug manufacturer interference with 340B contract pharmacy arrangements. It also would prohibit pharmacy benefit manager and payor practices that lower reimbursement for 340B-purchased drugs.

Read More »

A Cheat Sheet to New Groups that Use “340B” in Their Names

Cheat Sheet
340B Report Publisher and CEO Ted Slafsky's latest column for Verity Solutions is a cheat sheet for the growing number of groups using "340B" in their names.

With so many advocacy groups using the term “340B” in their name these days, it’s easy to confuse one with another. Ted Slafsky’s latest column for Verity Solutions is a guide to the menagerie.

Slafsky, publisher and CEO of 340B

Read More »

340B Recertification for CDC Grantees Starts May 8

Recertification
Annual 340B recertification for CDC grantees will be May 8 through June 5.

This year’s annual 340B recertification period for U.S. Centers for Disease Prevention and Control grantees—Title X family planning, sexually transmitted disease, and tuberculosis clinics—will be May 8 through June 5, the U.S. Health Resources and Services Administration said Tuesday.

Recertification

Read More »

In Surprise Move, Pennsylvania Wants 340B Modifiers on Medicaid Managed Care Drugs

Pennsylvania
Pennsylvania 340B covered entities say they were blindsided by the state's disclosure last week that it wants drug claims billed to Medicaid managed care organizations to include a modifier showing if the prescription was filled with a 340B-purchased drug.

Pennsylvania health centers are upset about what they say was the state Medicaid office’s disclosure without warning last week that, starting July 1, it wants drug claims billed to Medicaid managed care organizations to include a modifier showing if the

Read More »

Iowa Set to Enact Nation’s 25th 340B Nondiscrimination Law

Iowa state capitol
The Iowa Senate last week passed a 340B nondiscrimination bill 49-1, sending it to Gov. Kim Reynolds. The House passed it earlier 98-0.

The Iowa Senate last week passed a House-approved bill banning pharmacy benefit manager and payor discrimination against 340B covered entities and their contract pharmacies, including reimbursing the entities at a lower rate than non-340B providers.

The Senate voted 49-1 on

Read More »

Daiichi-Sankyo Offering Refunds for 340B Overcharges on Two Drugs

Enhertu
Daiichi-Sankyo is offering refunds for 340B overcharges on its breast cancer drug Enhertu and cholesterol drug Welchol for Oral Suspension.

Drug manufacturer Daiichi-Sankyo is offering 340B covered entities refunds for overcharges on metastatic breast cancer treatment Enhertu during Q1 2020 and on cholesterol medication Welchol for Oral Suspension during Q1 2022 and Q4 2022.

The U.S. Health Resources and Services

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report